Medicare Now Reimburses Cancer Patients for Granisetron Tablets

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

Medicare will reimburse cancer patients for granisetron hydrochloride (Kytril) tablets, announced SmithKline Beecham. Granistetron is indicated for the prevention of chemo- therapy-induced nausea and vomiting.

Medicare will reimburse cancer patients for granisetron hydrochloride (Kytril) tablets, announced SmithKline Beecham. Granistetron is indicated for the prevention of chemo- therapy-induced nausea and vomiting.

Until this year, Medicare patients were reimbursed only for oral antiemetics administered with select oral chemotherapies. Granistetron is one of the few oral medications reimbursed by Medicare when used in a hospital outpatient setting or physician’s office. This change in policy is especially significant because the majority of cancer patients receive chemotherapy treatments in an outpatient setting, said experts, and more than half of all cancer patients are over the age of 65 years and, thus, potential Medicare recipients.

Greater Patient Access to Oral Antiemetics

"Oral antiemetics, such as granistetron, play a crucial role in cancer treatment, especially since studies have shown that they offer efficacy comparable to intravenous antiemetics. Even though the majority of chemotherapy treatments are administered intravenously, Medicare has only, to date, covered oral antiemetics that are administered with certain oral chemotherapy treatments. As a result, many Medicare patients undergoing chemotherapy, were not prescribed oral antiemetics. Now, more patients will be given access to oral antiemetics which are cost-effective, require less administration time for health care providers, and are more convenient for patients," said Myron Goldsmith, MD, executive director of development, City of Hope Oncology Network in California, and a key supporter of the new legislation.

"We are pleased that Medicare has taken this important step to improve the lives of cancer patients by ensuring that all beneficiaries are reimbursed for oral antiemetic medications," said Diane Blum, executive director, Cancer Care.

More than 75% of patients receiving combination chemotherapy experience nausea and vomiting, which can significantly affect their ability to maintain daily functioning. The more widespread use of combination chemotherapy regimens and high-dose chemotherapies has made chemotherapy-induced vomiting even more severe.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content